Clinical Trails
In a clinical trial, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or changes to participants' behaviour, such as diet. Clinical trials may compare a new medical approach to a standard one that is already available, to a placebo that contains no active ingredients, or to no intervention. Some clinical trials compare interventions that are already available to each other. When a new product or approach is being studied, it is not usually known whether it will be helpful, harmful, or no different than available alternatives (including no intervention). The investigators try to determine the safety and efficacy of the intervention by measuring certain outcomes in the participants. Preclinical trials are early experiments performed in the lab, prior to being tested in humans. This early research helps to identify potential treatments that are unsafe or ineffective. Clinical trials used in drug development are sometimes described by phase. These phases are defined by the Food and Drug Administration (FDA).
- Pre-clinical Studies
Related Conference of Clinical Trails
Clinical Trails Conference Speakers
Recommended Sessions
- Bioequivalence Protocols: In vivo/ In vitro studies
- Contract Research Organization
- Advances in BABE
- Assessment of Bioequivalence
- BA/BE studies of Biologics and Biosimilars
- Bioavailability
- Bioequivalence
- Challenges in Drug Design
- Challenges in Drug Development
- Clinical Pharmacology and Therapeutics
- Clinical Trails
- Factors Affecting Bioavailability
- Managing BA/BE Studies
- Nutrient Bioavailability
- Pharma Clinical Trails
- Pharmaceutical Industry: Entrepreneurs Investment Meet
- Regulatory Requirements for Bioequivalence
- Significance of BA/BE Studies
- Study Designs
Related Journals
Are you interested in
- 3-D Structure Determination - Structural Biology 2025 (Germany)
- Advancements in structural Biology - Structural Biology 2025 (Germany)
- Biochemistry - Glycobiology 2025 (Germany)
- Biochemistry and Biophysics - Structural Biology 2025 (Germany)
- Computational Approach in Structural Biology - Structural Biology 2025 (Germany)
- Drug Designing and Biomarkers - Structural Biology 2025 (Germany)
- Evolution of Glycan Diversity - Glycobiology 2025 (Germany)
- Frontiers in Structural Biology - Structural Biology 2025 (Germany)
- Gene regulation and Cell Signalling - Structural Biology 2025 (Germany)
- Genomics and Metabolomics - Glycobiology 2025 (Germany)
- Glycans in Diseases and Therapeutics - Glycobiology 2025 (Germany)
- Glycans in Drug Design - Glycobiology 2025 (Germany)
- Glycan’s - Glycobiology 2025 (Germany)
- Glycobiology - Glycobiology 2025 (Germany)
- Glycochemistry - Glycobiology 2025 (Germany)
- Glycoimmunology - Glycobiology 2025 (Germany)
- Glycoinformatics - Glycobiology 2025 (Germany)
- Glycolipids and Glycopeptides - Glycobiology 2025 (Germany)
- Glyconeurobiology - Glycobiology 2025 (Germany)
- Glycopathology - Glycobiology 2025 (Germany)
- Glycosience - Glycobiology 2025 (Germany)
- Hybrid approaches in Structure prediction - Structural Biology 2025 (Germany)
- Molecular Biology - Structural Biology 2025 (Germany)
- Molecular biology techniques - Structural Biology 2025 (Germany)
- Molecular Modelling and Dynamics - Structural Biology 2025 (Germany)
- Proteoglycan and Sialic acid - Glycobiology 2025 (Germany)
- Proteomics and Genomics - Structural Biology 2025 (Germany)
- Recent Advances in Glycobiology - Glycobiology 2025 (Germany)
- Sequencing Analysis - Structural Biology 2025 (Germany)
- Structural Bioinformatics - Structural Biology 2025 (Germany)
- Structural Biology - Structural Biology 2025 (Germany)
- Structural Biology Databases - Structural Biology 2025 (Germany)
- Structural Biology in Cancer Research - Structural Biology 2025 (Germany)
- Structural Enzymology - Structural Biology 2025 (Germany)
- Synthesis and Biological Role of Glycans - Glycobiology 2025 (Germany)